ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
MiNK Therapeutics Inc

MiNK Therapeutics Inc (INKT)

1.02
-0.02
(-1.92%)
Closed May 16 4:00PM
1.0494
0.00
(0.00%)
After Hours: 7:58PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.0494
Bid
1.00
Ask
1.05
Volume
76,614
0.98 Day's Range 1.0999
0.75 52 Week Range 3.34
Market Cap
Previous Close
1.04
Open
1.06
Last Trade
89
@
1.02
Last Trade Time
Financial Volume
$ 79,586
VWAP
1.0388
Average Volume (3m)
194,990
Shares Outstanding
34,519,540
Dividend Yield
-
PE Ratio
-1.57
Earnings Per Share (EPS)
-0.65
Revenue
-
Net Profit
-22.46M

About MiNK Therapeutics Inc

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses. MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
MiNK Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker INKT. The last closing price for MiNK Therapeutics was $1.04. Over the last year, MiNK Therapeutics shares have traded in a share price range of $ 0.75 to $ 3.34.

MiNK Therapeutics currently has 34,519,540 shares outstanding. The market capitalization of MiNK Therapeutics is $35.21 million. MiNK Therapeutics has a price to earnings ratio (PE ratio) of -1.57.

INKT Latest News

MiNK Reports First Quarter 2024 Results

Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS)AACR presentation reported...

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a...

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid modelsMiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK...

U.S. Index Futures Rise as Fed’s Dovish Outlook Spurs Positive Investor Sentiment; Oil Prices See Minor Declines

U.S. index futures are showing an uptrend in Thursday’s pre-market, driven by the record close of the three major indexes in the previous session and the more “dovish” stance...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.119412.83870967740.931.30.8611823280.99821375CS
40.131114.27638026790.91831.30.863336570.98952557CS
120.109411.63829787230.941.90.781949901.09414514CS
260.00940.9038461538461.041.90.751190831.06346504CS
52-0.6506-38.27058823531.73.340.751009241.40664477CS
156-10.9906-91.284053156112.0422.1550.751204182.90466566CS
260-10.9906-91.284053156112.0422.1550.751204182.90466566CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CRKNCrown Electrokinetics Corporation
$ 0.2321
(402.38%)
3.12B
LSDILucy Scientific Discovery Inc
$ 1.5697
(207.78%)
69.27M
GWAVGreenwave Technology Solutions Inc
$ 0.149
(149.16%)
1.93B
TOIIWOncology Institute Inc
$ 0.0998
(134.82%)
6.38k
FFIEFaraday Future Intelligent Electric Inc
$ 1.6401
(132.64%)
1.14B
LGHLWLion Group Holding Ltd
$ 0.0041
(-28.07%)
40
SYTASiyata Mobile Inc
$ 2.51
(-27.87%)
622.62k
REKRRekor Systems Inc
$ 1.3811
(-24.12%)
5.92M
EYENEyenovia Inc
$ 0.8156
(-23.06%)
1.65M
RELIReliance Global Group Inc
$ 0.29
(-21.60%)
2.97M
CRKNCrown Electrokinetics Corporation
$ 0.2321
(402.38%)
3.12B
GWAVGreenwave Technology Solutions Inc
$ 0.149
(149.16%)
1.93B
FFIEFaraday Future Intelligent Electric Inc
$ 1.6401
(132.64%)
1.14B
PEGYPineapple Energy Inc
$ 0.1467
(68.81%)
472.39M
SINTSiNtx Technologies Inc
$ 0.139999
(9.72%)
381.41M

INKT Discussion

View Posts
Awl416 Awl416 4 days ago
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
👍️0
Muhbruh Muhbruh 1 month ago
INKT for swing Preclinical data is to be shared at AACR on April 8, 2024
Float 5m Insiders own 71.34% , had 9.68% 13D from 14/02/24 , No dilution
👍️0
Monksdream Monksdream 7 months ago
INKT under $2
👍️0
dia76ca dia76ca 2 years ago
Mink SITC 2022 posters are full of very exciting data! Here are some highlights.

1.Allogeneic unmodified iNKTs (agenT-797) show reductions in target and non-target lesions or disease stabilization in patients with solid
tumor cancers when administered alone [27%] and in combination with pembrolizumab (KEYTRUDA®) or nivolumab (OPDIVO®) [66%].
Phase 1 data show early signals of activity with disease stabilization in patients refractory to standard of care and those
who have progressed on KEYTRUDA or OPDIVO.
agenT-797 preferentially kills tumor-promoting M2 macrophages while preserving pro-inflammatory M1 macrophages
associated with anti-tumor responses.
agenT-797 can be dosed up to 1000x106
cells without lymphodepletion showing no signs of neurotoxicity and cytokine release syndrome (CRS grade ≥ 3).

2.Allo-iNKTs show signals of durable disease stabilization and modulation of M-spike protein seen in heavily pre-treated r/r multiple myeloma patients (2/8) after ≥6 prior lines of therapy.

3. agenT-797 shows 70% survival in severe viral ARDS compared to site reference controls (~10%); potential for a variant agnostic approach
to infections. In Phase 1/2 study, agenT-797 shows survival of 70% in mechanically ventilated patients compared to ~10% in a comparative case control population.

4. Increased 90-day survival in a subgroup of patients on respiratory bypass (ECMO) of 75% compared to 30% in a
comparative cohort with median survival of 119.5 vs 47 days.
agenT-797 demonstrates a favorable safety profile. Only 1 grade ≥3 treatment related adverse event and no CRS was
observed. agenT-797 treatment was associated with a reduction in secondary infections, including reduced incidence of pneumonia at
the highest dose level, a driver of ICU mortality.

5. MiNK’s FAP-CAR-iNKT therapeutic candidate, MiNK-215, demonstrates robust efficacy in non small cell lung cancer (NSCLC) preclinical
models, promoting curative responses, eliminating tumor burden in the lungs, and enhancing tumor specific CD8+ T cell infiltration
through tumor stroma.
FAP-CAR-iNKT demonstrates a drastic increase of CD8+ T cells infiltrating the tumor and significantly increased tumor
killing compared to T cells in murine models.
MiNK-215 shows robust preclinical efficacy towards tumor expressing FAP (FAP+ cancer model), underscoring potential to
target FAP+ tumors.

6. MiNK-413 is a differentiated allogeneic IL-15-armored-BCMA-CAR-iNKT therapeutic candidate, a next generation approach designed to
overcome the limitations of current autologous cell therapies.
MiNK-413 demonstrates superior tumor clearance in a systemic multiple myeloma models, compared to control BCMA-CAR.
Armoring MiNK-413 with soluble IL-15 enables prolonged persistence, which may translate to increased durability in patients.
MiNK-413 has the potential to target a broader population of patients with multiple myeloma.

7. MiNK’s proprietary CARDIS platform enables high-throughput rapid selection and optimization of functional CARs, like
MiNK-413 (IL-15-armored-BCMA-CAR-iNKT) and MiNK-215 (FAP-CAR-iNKT).

Allo-iNKTs (agenT-797) reinvigorate partially exhausted T cells and improve effector functions within the tumor microenvironment; critical
mechanisms in rescuing PD-1 refractory tumors.
In addition to their direct anti-tumor activity, allogeneic iNKT cells (agenT-797) improve immune effector function of immune
cells in the tumor microenvironment.
agenT-797 restores the cytotoxic capacity, activation, and cytokine production of partially exhausted T cells. agenT-797 preferentially kills tumor-promoting M2 macrophages while preserving pro-inflammatory M1 macrophages associated with anti-tumor responses.
agenT-797 activates dendritic cells, which can promote activation of T cells through enhanced antigen presentation.

The full poster presentations can be accessed on the publication section of MiNK’s website at https://minktherapeutics.com/publications/.
👍️0
dia76ca dia76ca 2 years ago
ARDS data will be important. BARDA support is a big deal.
👍️0
dia76ca dia76ca 2 years ago
Very interesting technology. Deserves a board.
👍️0

Your Recent History

Delayed Upgrade Clock